Now showing items 1-6 of 6
Biomarkers in Bladder Cancer Surveillance
Aim: This is a narrative review with an aim to summarise and describe urinary biomarkers in the surveillance of non-muscle-invasive bladder cancer (NMIBC). It provides a summary of FDA-approved protein biomarkers along ...
Secondary Neoplasms of the Urinary Bladder-Clinical Management and Oncological Outcomes
Background: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however there is limited literature reporting management and survival. This is the largest single centre series presented in current ...
Urinary biomarkers in bladder cancer: A review of the current landscape and future directions
This narrative review aims to describe established and emerging urinary biomarkers in the diagnosis and surveillance of non-muscle invasive bladder cancer (NMIBC). It provides a comprehensive account of classical, FDA-approved ...
Urinary Biomarkers: Mitigating Diagnostic Delays of Bladder Cancer in the COVID-19 era
The COVID-19 pandemic has resulted in a substantial increase in waiting times for cystoscopies, prompting concerns of delayed diagnoses and substandard surveillance of bladder cancer. Expanding the role of urinary biomarkers ...
Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers
Background/Aim: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and ...
Outcomes of the 2019 Novel Coronavirus in patients with or without a history of cancer - a multi-centre North London experience
Background Four months after the first known case of the 2019 novel coronavirus disease (COVID-19), on the 11th March 2020, the WHO declared the outbreak a pandemic and acknowledged the potential to overwhelm national ...